Navigation Links
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
Date:9/17/2011

ster, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (Media)
Arvind Sood, 805-447-1060 (Investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

(1)  "Facts and statistics about osteoporosis and its impact." International
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
2. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
3. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
4. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
5. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
6. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
9. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
10. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
11. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 6, 2015 /CNW/ - Celebrities, bloggers and influencers across ... to spread the important message that melanoma prevention begins with ... Maria Sharapova , Hilary Duff , and parenting author ... out to their networks on Monday to share this poignant ... The David Cornfield Melanoma Fund (DCMF)-producers ...
(Date:5/6/2015)... May 6, 2015 CVS Health (NYSE: CVS ) ... Baltimore locations that sustained heavy fire damage during protests ... Baltimore over the past week or so, ... ahead," said CVS Health President and CEO Larry Merlo . ... to better health. There is no better way that we can ...
(Date:5/6/2015)... 06, 2015 Research and Markets ... the "Cannulas Market by Product (Nasal, Arterial, ... Microcannula), Material (Plastic, Metal) & End Users (Hospitals, ... report to their offering. The ... a CAGR of 5.6% from 2015 to 2020 ...
Breaking Medicine Technology:Celebrities Tweet Their Support of Melanoma Awareness Month and #newfamilyrule 2CVS Health Announces it Will Rebuild Baltimore CVS/pharmacy Locations 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 3
... Progress in Advancing Second-Generation ... CCR9 Drug towards ... announced the completion of enrollment of 436 patients in the,company,s ... a Phase II/III clinical trial of Traficet-EN(TM),(CCX282-B) in patients with ...
... DIEGO, June 12 Vical Incorporated,(Nasdaq: VICL ... of cash payments,and equity investments from AnGes MG, ... funding of the company,s ongoing,Allovectin-7(R) Phase 3 metastatic ... equity investments, Vical has received $15.3 million to ...
Cached Medicine Technology:ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 3ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 4ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 5ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 6Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4
(Date:5/7/2015)... NE (PRWEB) May 07, 2015 Aureus ... in travel nursing jobs and a variety ... health, has released an infographic spotlighting top theme ... infographic is aimed at thrill-seeking mobile healthcare professionals who ... , Travel healthcare careers offer an opportunity for the ...
(Date:5/7/2015)... and Washington, DC (PRWEB) May 07, 2015 ... Nebraska and Iowa -- CHI Health Bergan Mercy, ... in Omaha; CHI Health Midlands in Papillion, Neb.; ... -- have been recognized for achieving high-quality standards ... an independent, physician-led organization dedicated to best practices ...
(Date:5/6/2015)... Church, VA (PRWEB) May 07, 2015 ... Impact of NSF/IPEC/ANSI 363-2014, **FDAnews Webinar**, May 27, ... http://www.fdanews.com/NewGMPStandards , Most drugs contain 70-90% ... aids, binding agents or other purposes that facilitate ... globalization of the pharma industry, combined with a ...
(Date:5/6/2015)... 06, 2015 With an estimated 300,000 ... to its potentially dangerous health effects, the Horizon Foundation ... BEAM (Breathe Easier with Asthma Management) – to improve ... being funded through a $500,000 foundation grant to the ... is implementing BEAM throughout the state. , “While asthma ...
(Date:5/6/2015)... Edvance360 LMS-SN , a leader in ... Software & Information Industry Association's (SIIA) 30th annual ... Learning Management Solution" category. Edvance360 LMS-SN won the ... this award seven years running, continued proof that Edvance360 ... industry. , "The honor of being a CODiE ...
Breaking Medicine News(10 mins):Health News:Get to Know the Top Theme Parks: Aureus Medical Releases Infographic for the Travel Nurse and Other Travel Healthcare Professionals 2Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 2Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 3Health News:FDAnews Announces — New Standards for Excipient GMPs: Analyzing the Impact of NSF/IPEC/ANSI 363-2014 Webinar, May 27, 2015 2Health News:FDAnews Announces — New Standards for Excipient GMPs: Analyzing the Impact of NSF/IPEC/ANSI 363-2014 Webinar, May 27, 2015 3Health News:The Horizon Foundation for New Jersey and Boys & Girls Clubs in New Jersey Join Forces to Help Children with Asthma 2Health News:The Horizon Foundation for New Jersey and Boys & Girls Clubs in New Jersey Join Forces to Help Children with Asthma 3Health News:The Horizon Foundation for New Jersey and Boys & Girls Clubs in New Jersey Join Forces to Help Children with Asthma 4Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 2Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 3
... might even harm cognitive function , , MONDAY, May 12 (HealthDay ... that daily use of two popular pain-relieving drugs, Celebrex and ... family history of Alzheimer,s disease. , In fact, naproxen, which ... have a deleterious effect on cognitive function, the study found. ...
... Further Enhancing AnComm,s Ability To Help Texas Schools Stay ... ,Talk About It(R),-- the nation,s first and only anonymous ... pleased to announce the addition of,Catherine Toohey, M.Ed. to ... help Texas schools stay safe and avoid tragedies, Ms. ...
... reserved,for lighthearted fun and entertainment, the hallways of ... of gathering Monday, as child-health,and education experts and ... in Jordan. Her Majesty Queen Rania Al Abdullah ... there, bringing some,welcomed news about the Kingdom,s progress. ...
... Clinical Sciences performed the surgery that restored sight to 7-year-old ... Runnells. , "We are excited for Dixie," said Grozdanic. "She ... really worked. She was gradually going down visually and we ... quality of life." , "She is my pet and my ...
... Inc., a developer of advanced medical devices for ... that it has enrolled its,first patient in the ... U.S. registry study of the company,s OmniWave(TM) Endovascular,System ... limb ischemia (ALI). All patients enrolled in the ...
... serialization initiatives, CRANBURY, N.J., May 12 ... Systems (PES) for the pharmaceutical,industry, today announced ... central engineering and professional services,teams. The company ... to support,rapid worldwide deployments; specifically, the increasing ...
Cached Medicine News:Health News:Celebrex, Naproxen Won't Prevent Mental Decline 2Health News:Celebrex, Naproxen Won't Prevent Mental Decline 3Health News:AnComm's 'Talk About It(R)' Adds New School Safety Specialist 2Health News:Queen Rania Launches Situation Analysis of Children in Jordan Highlighting Jordan's Progress in Improving Quality of Life; 6 Ministers Commit to Further Improving Results 2Health News:Queen Rania Launches Situation Analysis of Children in Jordan Highlighting Jordan's Progress in Improving Quality of Life; 6 Ministers Commit to Further Improving Results 3Health News:Queen Rania Launches Situation Analysis of Children in Jordan Highlighting Jordan's Progress in Improving Quality of Life; 6 Ministers Commit to Further Improving Results 4Health News:ISU researcher performs first veterinary corneal implant procedure in US 2Health News:ISU researcher performs first veterinary corneal implant procedure in US 3Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Systech Augments Key Departments to Drive Operational Excellence and International Support 2Health News:Systech Augments Key Departments to Drive Operational Excellence and International Support 3
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistain SLS Linear Stainer is an economical mid-size linear stainer for staining procedures that do not require heat....
... a manual rotary microtome for routine paraffin ... designed to address repetitive stress injury. The ... tray, organizer storage tray and a resettable ... and may be disengaged at the user?s ...
... The Netmon remote monitoring service allows ... programmed and monitored from any location ... The service enhances preventive maintenance capabilities. ... access the unit (with your permission) ...
Medicine Products: